Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Complete Genomics, a human genome sequencing company, has formed a collaboration with the Broad Institute of MIT and Harvard to conduct complete human genome sequencing pilot studies of two cancers - glioblastoma and melanoma.
Subscribe to our email newsletter
Throug this collaboration, Complete Genomics will use its DNA sequencing technology to sequence five genomes from samples provided by the Broad Institute.
The first genome sequenced will be a test case that has already been studied extensively by the scientific community. The other four genomes are tumor and matched-pair normals; one pair will be used to study glioblastoma and the other melanoma.
Clifford Reid, chairman, president and CEO of Complete Genomics, said: “Our newly released, proof-of-concept sequencing data have been well received by the scientific community, and we are now looking forward to demonstrating our technology’s potential to reveal new avenues of medical research.
“We are very pleased to be working with such a prestigious organization as the Broad Institute on a project that may provide additional insight into the pathways responsible for these deadly diseases.”